a(CHEBI:glyceraldehyde)

Entity

Name

glyceraldehyde

Namespace

chebi

Namespace Version

20180906

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells. PubMed:26304819

A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells. PubMed:26304819

A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells. PubMed:26304819

GA dose-dependently increased the production of GA-AGEs in SH-SY5Y cells. PubMed:26304819

Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers, were increased when the concentration of GA added was greater than 0.7 mM. PubMed:26304819

Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers, were increased when the concentration of GA added was greater than 0.7 mM. PubMed:26304819

Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers, were increased when the concentration of GA added was greater than 0.7 mM. PubMed:26304819

Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers, were increased when the concentration of GA added was greater than 0.7 mM. PubMed:26304819

Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers, were increased when the concentration of GA added was greater than 0.7 mM. PubMed:26304819